7447.T
The company operates in the healthcare services and equipment sector, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Business. 7447.T is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
7447.T is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not provided in the available data.
The company maintains a strong liquidity position, with a current ratio of 14.44 and a cash and equivalents balance of 24,246,113,000 JPY, indicating a robust ability to meet short-term obligations. The price-to-book ratio of 1.21 and a debt-to-equity ratio of 0.0 suggest a conservative capital structure with no long-term debt, which reduces financial risk.
Profitability metrics show a return on equity (ROE) of 6.23% and a return on assets (ROA) of 5.76%, both of which are in line with the industry's preferred metrics for capital efficiency and asset utilization. The company's operating income of 3,583,439,000 JPY and net income of 2,573,482,000 JPY reflect a healthy margin profile, with a gross profit of 6,712,011,000 JPY supporting strong cost control.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks, though the absence of long-term debt and strong liquidity mitigate some of these concerns.
Looking ahead, the company is projected to grow revenue from 16,983,840,000 JPY to 17,700,000,000 JPY, representing a modest increase of 4.2%. Analysts expect earnings per share (EPS) to rise from 83.24 JPY to 91.80 JPY, indicating a positive earnings outlook. The company's free cash flow of 575,237,000 JPY and operating cash flow of 2,180,901,000 JPY support its ability to fund operations and potentially reinvest in growth.
The company's risk profile is low, with no immediate liquidity or dilution flags detected. The absence of long-term debt and a low dilution risk suggest a stable capital structure. The company's valuation multiples, including a price-to-earnings ratio of 19.51 and an enterprise value-to-EBITDA ratio of 7.24, are in line with industry norms, indicating a fairly valued business.
Recent financial filings and transcripts do not indicate any material changes in the company's operations or strategy. The company's strong cash position and conservative financial structure suggest a focus on stability and long-term value creation.
- The company has a strong liquidity position with a current ratio of 14.44 and no long-term debt.
- Profitability metrics, including ROE of 6.23% and ROA of 5.76%, are in line with industry standards.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Analysts project a modest revenue growth of 4.2% and an increase in EPS from 83.24 JPY to 91.80 JPY.
- The company's valuation multiples are in line with industry norms, indicating a fairly valued business.
- The company's risk profile is low, with no immediate liquidity or dilution flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 91,80 |
| Revenue | —no estimate | —no estimate | 17,7B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 7447.T Market data — financials · 2026-05-27
- Nagaileben Co Ltd Market data — analyst estimates · 2026-05-27